Table 1.
Patient characteristics
| Variable | Group 1 (single dose) | Group 2 (all included) | Group 3 (all excluded) | All doses |
|---|---|---|---|---|
| Diagnosis: all (patients/doses) | 18/20 | 19/25 | 9/19 | 24/44 |
| Intracerebral hemorrhage | 4/4 | 4/4 | 1/2 | 5/6 |
| Subarachnoid hemorrhage | 4/5 | 4/6 | 1/2 | 5/8 |
| Brain tumor | 3/3 | 4/4 | 5/11 | 5/15 |
| Guillain–Barré syndrome | 2/3 | 2/3 | 0 | 2/3 |
| Traumatic brain injury | 2/2 | 2/3 | 0 | 2/3 |
| Other* | 3/3 | 3/5 | 2/4 | 5/9 |
| Gender (male/female), patients | 13/5 | 14/6 | 7/2 | 13/11 |
| Conivaptan doses (20/40 mg) | 17/3 | 20/5 | 11/8 | 31/13 |
| Fluid type (NS/HS) | 14/6 | 18/7 | 9/10 | 27/17 |
| Admission GCS (median, IQR) | 14 (12.75–15) | 14 (9.5–15) | 13 (3–14) | 13.5 (8.5–15) |
| Admission GCS ≤8 (%) | 7% | 18% | 43% | 25% |
| Duration of hyponatremia prior to dose (median, IQR) | 22 h (10–48) | 20 h (10–48) | 9 h (0–24) | 12.5 h (6–24) |
*
Other diagnoses included subdural hematoma, ischemic stroke, and normal-pressure hydrocephalus
Note: All doses forming group 1 are also included in group 2
NS normal saline, HS hypertonic saline